SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association For Continuing Education


Course Directors
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Deborah Paschal, CRNP
Philadelphia, PA

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Course Reviewer
Robert L. Gillespie, MD, FACC, FASE, FASNC
Immediate Past Chairman of the Board
Association of Black Cardiologists
Director of Nuclear Imaging
Sharp Rees-Stealy Medical Group
San Diego, CA

Title
: Putting Emerging Lipids Data into Practice: New Treatments and Opportunities to Reduce Cardiovascular Risk
Activity/Course #:
: NCME342
Cost:
: Free
Release/Start Date:
: Jan 05 2018
Expiration Date:
: Jan 04 2019
Topics:
: Cardiovascular
Target Audience:
: Primary Care Providers
Format:
: Monograph
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Statins have been the mainstay of pharmacotherapy for dyslipidemia and reduction of cardiovascular risk. The PCSK9 inhibitors are a new and exciting treatment option for hyperlipidemia that are changing the way those patients at the highest risk are being managed. Over the past several years, there have been several updates to ACC/AHA lipid treatment recommendations which leave many clinicians wondering what the best strategies are for their patients. This educational program will discuss an approach to integrating new data into lipid management strategies for further improving cardiovascular outcomes in the highest risk patients.

Learning Objective(s):

After completing this program participants should be able to:

  1. Review current recommendations for the use of non-statin therapies in the management of dyslipidemia
  2. Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction
  3. Describe the findings from recent trials of dyslipidemia treatments on cardiovascular outcomes
  4. Integrate new data into treatment strategies for further improving cardiovascular outcomes in the highest risk patients

How To Obtain Your CME Certificate

  1. Register for the course at www.naceonline.com.
  2. Complete the pre-test.
  3. View the content.
  4. Complete and submit the post-test and evaluation.
  5. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  6. Print your CME certificate.

Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Association of Black Cardiologists designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education(which includes 0.75 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosures are provided below.

Robert L. Gillespie, MD, FACC, FASE, FASNC, Course Reviewer, is a speaker for Astellas and Boston Scientific. He also serves as a consultant for Boston Scientific.

Gregg Sherman, MD, Co-Course Director, has no relationships to disclose.

Deborah Paschal, CRNP, Co-Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Cassandra A. McCullough, MBA, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This activity is supported by educational funding provided by Amgen.